Wakefit Innovations IPO Price: ₹1008 to ₹1062 per share
IPO Dates: 8th December 2025 – 10th December 2025
Company Overview
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company engaged in developing, manufacturing, and marketing products across women’s healthcare, cardiology, pain management, urology, and various other therapeutic areas.
The company’s diverse product range addresses key healthcare needs, supported by strong R&D, quality manufacturing, and a robust distribution network.
Product & Brand Portfolio
As of June 30, 2025, the company offers 71 brands across multiple therapeutic categories, including:
- Women’s healthcare
- Cardio-diabeto
- Pain management
- Urology
- Multispecialty segments (vitamins/minerals/nutrition, gastrointestinal, respiratory)
Marketing & Distribution Network
Corona Remedies has a pan-India presence with:
- 2,671 medical representatives
- Operations across 22 states
This strong on-ground network enables effective engagement with healthcare professionals and hospitals, strengthening its footprint in the Indian Pharmaceutical Market (IPM) and ensuring deep penetration across therapeutic areas.
Manufacturing Capabilities
The company operates two manufacturing facilities located in Gujarat, with a combined installed formulation capacity of 1,285.44 million units per annum.
These facilities follow stringent quality standards and support a diverse product pipeline.
Competitive Strengths
- Second fastest growing company among the top 30 Indian pharmaceutical players by domestic sales (MAT June 2022 to MAT June 2025).
- Proven ability to build a diversified portfolio, including strong “engine” brands in key therapies.
- Extensive pan-India sales network with a focus on the “middle of the pyramid” patient segment.
- Quality-driven manufacturing with strong R&D capabilities supporting differentiated product development
- Experienced, qualified, and entrepreneurial management team backed by marquee investors.
Bidding Starts In
Corona Remedies IPO Specifics:
| IPO Date | December 8, 2025 to December 10, 2025 |
| Face Value | ₹10 per share |
| Price Band | ₹1008 to ₹1062 per share |
| Lot Size | 14 Shares |
| Sale Type | Offer For Sale |
| Total Issue Size | 61,71,101 shares (aggregating up to ₹655.37 Cr) |
| Offer for Sale | 1,93,42,461 shares (aggregating up to ₹377.18 Cr) |
| Employee Discount | ₹54.00 |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 6,11,60,088 shares |
| Share Holding Post Issue | 6,11,60,088 shares |
Corona Remedies IPO Timetable (Important Dates)
| IPO Open Date | Mon, Dec 8, 2025 |
| IPO Close Date | Wed, Dec 10, 2025 |
| Tentative Allotment | Thu, Dec 11, 2025 |
| Initiation of Refunds | Fri, Dec 12, 2025 |
| Credit of Shares to Demat | Fri, Dec 12, 2025 |
| Listing Date | Mon, Dec 15, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on Wed, Dec 10, 2025 |
Corona Remedies IPO Lot Size
Bidders have the opportunity to bid for a minimum of 14 shares, with the option to increase in multiples. The table below outlines the minimum and maximum investment thresholds for both retail investors and High Net Worth Individuals (HNIs), specifying the corresponding number of shares and amounts involved.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 14 | ₹14,868 |
| Retail (Max) | 13 | 182 | ₹1,93,284 |
| S-HNI (Min) | 14 | 196 | ₹2,08,152 |
| S-HNI (Max) | 67 | 938 | ₹9,96,156 |
| B-HNI (Min) | 68 | 952 | ₹10,11,024 |
Corona Remedies IPO Reservation
| QIB Shares Offered | Not less than 50% of the Net Offer |
| Retail Shares Offered | Not more than 35% of the Net Offer |
| NII (HNI) Shares Offered | Not more than 15% of the Net Offer |
Corona Remedies IPO Financial Information
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 1,012.38 | 929.86 | 830.58 | 595.02 |
| Total Income | 348.56 | 1,202.35 | 1,020.93 | 891.10 |
| Profit After Tax | 46.20 | 149.43 | 90.50 | 84.93 |
| EBITDA | 71.80 | 245.91 | 161.19 | 135.03 |
| NET Worth | 607.02 | 606.34 | 480.41 | 408.52 |
| Reserves and Surplus | 545.86 | 545.18 | 419.25 | 347.36 |
| Total Borrowing | 106.65 | 62.70 | 134.14 | 2.33 |
Key Performance Indicator – Corona Remedies IPO
| KPI | Values |
|---|---|
| ROE | 27.50% |
| ROCE | 41.32% |
| RoNW | 24.65% |
| Debt/Equity | 0.10 |
| PAT Margin | 12.49% |
| EBITDA Margin | 20.55% |
| Price to Book Value | 10.71 |
| Market Capitalization | ₹6,495.20 Cr. |
| EPS | 24.43 |
| P/E (x) | 43.47 |
Prospectus Links:
Prospectus: Official documents that provide detailed information about the IPO and the company.
Wakefit Innovations Limited IPO RHP
News Desk
